No, Male Partners Should NOT Be Treated for Recurrent Bacterial Vaginosis—With One Important Exception
Routine treatment of male sexual partners is NOT recommended for women with recurrent bacterial vaginosis, as established guidelines clearly state that partner treatment does not reduce recurrence rates 1, 2, 1. However, groundbreaking 2025 evidence demonstrates that combined oral AND topical antimicrobial therapy for male partners significantly reduces BV recurrence, cutting rates from 63% to 35% (absolute risk reduction of 2.6 recurrences per person-year, P<0.001) 3.
The Evidence Landscape
Traditional Guidelines: No Partner Treatment
Multiple CDC guidelines from 1993-1998 consistently state that:
- Treatment of male partners does not alter the clinical course of BV in women during treatment 1
- Partner treatment does not influence relapse or recurrence rates 1
- Male partners are typically asymptomatic 1
- BV is not considered exclusively an STD, though associated with sexual activity 1
These guidelines established the standard of care: treat the woman only, not her partner 2, 1.
The Game-Changing 2025 StepUp Trial
The StepUp trial fundamentally challenges this paradigm 3. This randomized controlled trial was stopped early by the data safety monitoring board because treating women alone was clearly inferior to treating both partners. Key findings:
Treatment Protocol That Works:
- Male partners: Metronidazole 400mg tablets PLUS 2% clindamycin cream to penile skin, both twice daily for 7 days
- Female partners: Standard first-line antimicrobial therapy
Results:
- Recurrence in partner-treatment group: 35% (24/69 women)
- Recurrence in control group: 63% (43/68 women)
- This represents a 44% relative risk reduction
Why Previous Studies Failed
A 2026 meta-analysis of six RCTs involving 953 couples found no benefit from male partner treatment (RR = 0.97; 95% CI 0.76-1.22) 4. However, when the StepUp trial was excluded from sensitivity analysis, heterogeneity disappeared—revealing that oral-only therapy doesn't work 4.
A 2021 trial using oral metronidazole alone in male partners showed no significant benefit (81% vs 80% failure rates) 5. The critical difference: topical therapy is essential.
The Biological Rationale
BV-associated bacteria colonize penile skin and can be sexually transmitted back to female partners 6. A 2018 pilot study demonstrated:
- Combined oral and topical treatment in males immediately altered penile microbiota composition (Bray-Curtis score 0.09 at day 8) 6
- Decreased prevalence and abundance of BV-associated bacteria on penile skin 6
- Treatment was well-tolerated with high adherence (>90% took prescribed medication) 6
Clinical Algorithm for Partner Treatment
When to Treat Male Partners:
YES - Treat both partners if:
- Woman has recurrent BV (≥2 episodes in past year)
- Monogamous heterosexual relationship
- Male partner willing and able to adhere to 7-day regimen
- No contraindications to metronidazole or clindamycin
NO - Treat woman only if:
- First episode of BV
- Non-monogamous relationship or multiple partners
- Male partner unable/unwilling to complete treatment
- Guideline-based care preferred in absence of recurrence
Treatment Regimen for Recurrent BV:
Female Partner:
- Metronidazole 500mg PO twice daily for 7 days
- OR alternative first-line therapy per guidelines
Male Partner (if treating):
- Metronidazole 400mg PO twice daily for 7 days
- PLUS Clindamycin 2% cream applied to entire penile skin (glans, shaft, foreskin if present) twice daily for 7 days
Critical Implementation Points:
- Both oral AND topical therapy are required for male partners—oral alone is ineffective 4, 5
- Advise alcohol avoidance during metronidazole treatment and for 24 hours after 1
- Counsel about expected side effects: nausea, headache, metallic taste 3
- Instruct couples to abstain from unprotected sex during treatment period 5
- Clindamycin cream is oil-based and may weaken latex condoms 2
Important Caveats and Pitfalls
Common Mistake: Prescribing oral metronidazole alone for male partners—this approach has been repeatedly shown ineffective 4, 5. The topical component targeting penile skin colonization is essential.
Adherence Matters: The 2021 trial showed that women whose male partners actually adhered to medication were less likely to fail treatment (adjusted RR 0.85, P=0.035) 5. Emphasize the importance of completing the full 7-day regimen.
Cost-Effectiveness: Partner treatment becomes cost-saving at uptake ≥28% in high-income settings and ≥2% in middle-income settings, with substantial savings at higher uptake rates 7. This supports broader implementation.
Guideline Evolution: The American College of Obstetricians and Gynecologists now advises partner therapy for recurrent BV, reflecting this paradigm shift 8. However, many older guidelines remain unchanged.
The Nuanced Recommendation
For first-episode BV: Follow established guidelines—treat the woman only 1, 2, 1.
For recurrent BV in monogamous relationships: The evidence strongly supports treating both partners with combined oral and topical therapy 3. This represents a fundamental shift from traditional practice, supported by high-quality RCT data that was compelling enough to stop the trial early for efficacy.
The key distinction is combined therapy—oral metronidazole plus topical clindamycin for male partners—not the oral-only approaches that failed in previous trials 4, 5.